| Cel-Sci's CEO feeling bullish after key developments (AMEX:CVM) | | Print | |
| Written by M.E.Garza | |||||||||||||||||||||||||||||||||||||||||
| Friday, 21 August 2009 12:18 | |||||||||||||||||||||||||||||||||||||||||
|
The strategic maneuver was primarily designed to not only pay off some convertible debt, but also to continue work on a somewhat secretive, yet exciting drug technology which would be directed at helping very ill patients infected with the current form of H1N1. "We are extremely pleased as this solidifies our balance sheet and allows us to buy out the convertible debt in the near term while taking care of our financial needs for the immediate future," said Kersten. "It will give us the latitude to continue our on-going tests in H1N1 and rheumatoid arthritis. It will allow us to move forward rapidly in the preparation for the Phase III trial for Multikine®, still the most important step for the Company. " Multikine® is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. The company's flagship product, is also the first of a new class of cancer immunotherapy drugs called Immune SIMULATORs which simulates the activities of a healthy person's immune system. "The deal was done at a 12.5% premium to the last financing only 60 days ago," said Kersten. "We are now in a much better position to move forward and the strength of balance sheet speaks for itself, as does our ability to raise money twice at improved prices and terms."
Disclosure: No positions BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (13)
M.E.Garza
said:
|
Company's biotechnology activates the immune system and targets the H1N1 flu's hemagglutinin molecule. The treatment apparently induces a defined immune response which could help infected swine flu patients.
TrackBack URI for this entry
Subscribe to this comment's feed|
... This company has a lot going for it! It isn't your run of the mill penny stock. It has built an excellent manufacturing facility for its production that is required for Phase III Multikline, it has a solid management team AND raising $4.4 m is a smart thing to do. The company only had enough cash to make it to Jan - Mar of 2010. Now let's look at a few factors: Institutional investors don't throw $4.4m to lose The stock price is pretty much given a floor of 0.45 with the agreed upon purchase price, and potentially 0.55 with the warrants. myself, having bought in at 0.40 means that I can securely state that we won't go below 0.45 - 0.55 over the long run. As for H1N1 - They might have something,but that's not what the REAL investor community is looking at. Day traders can make something (profit) on a short burst with the pump, but the long term is Multikline which has shown excellent efficacy results in Phase II and even if Phase III results end up being as much as 50% less than Phase II, the product is a WIN for the general public and us investors. Addiionally, how many penny stocks honestly start to get decent press from something other than "market watch, penny-blah, blah, blah"? CNNMoney doesn;t throw the typical penny stock releases that these 3rd world "press release" organizations do. The company and its strategies and product potential have a lot to be favored. Keep pumping it down in the short run if you want; only helps me to build to my share-level. I'll see you in 6 - 18 months and send you a post card from a really nice place. Bless you all |
|
M.E.Garza
said:
|
... Form 8-K for CEL SCI CORP 21-Aug-2009 Entry into a Material Definitive Agreement, Financial Statements and Exhibits Item 1.01 Entry Into a Material Definitive Agreement On August 20, 2009 CEL-SCI Corporation sold 9,701,000 shares of its common stock to a group of private investors for $4,365,450 or $0.45 per share. The investors also received warrants which entitle the investors to purchase 4,850,500 shares of CEL-SCI's common stock. The warrants may be exercised at any time on or after February 20, 2010 and on or prior to August 20, 2014 at a price of $0.55 per share. The closing of the transaction is expected to close on August 25, 2009. CEL-SCI has agreed to pay Chardan Capital Markets, LLC, the placement agent for this offering, a cash commission of $218,272. CEL-SCI has filed with the Securities and Exchange Commission a prospectus supplement to its shelf Registration Statement on Form S-3 registering the shares of common stock and warrants sold to the private investors. http://biz.yahoo.com/e/090821/cvm8-k.html |
|
M.E.Garza
said:
|
... I think it's very interesting that Cel Sci Corp filed this SEC Form 424B3 -- http://secfilings.com/searchresultswide.aspx?link=1&filingid=6767636 Since a 4 degrees Celsius fill and finish process can save drug manufacturers time and money, CEL-SCI believes it will be able to charge approximately $150,000 for an eight hour fill and finish "run". CEL-SCI does not know of any other facility in the United States which is able to provide cold 4 degrees Celsius finish and fill services on a contract basis. Interesting... |
|
M.E.Garza
said:
|
... I am two steps ahead of you Securities Man. I am interviewing Mr. Kersten about this and I can tell you that this is definitely an ACE up his sleeve. I won't go into too many details about this now, but this lab is definitely going to make CVM not only some money, but also into a big player. The management team over there is solid and they have some big plans to unveil in the coming weeks. |
|
M.E.Garza
said:
|
... The validation of the new facility should be within 2 months. So we can surely expect to hear something about that by end of October. This is a great stock and the fact that the company was able to raise 10 million in such a time shows the faith of investors in the company's future. This is a great buying opportunity!!! GLTA!!! |
|
M.E.Garza
said:
|
... You are welcome. I really do think this company has a very good team. Their turnover (staff) is almost zero and that speaks volumes to me about how much they believe in what they are doing. Through thick and thin they have stuck together. |
|
M.E.Garza
said:
|
... Interesting article here that talks about the technology: http://seekingalpha.com/article/153131-biotech-stocks-digging-for-gold-in-a-swine-s-snout?source=yahoo |
|
M.E.Garza
said:
|
... Also.. Here is a list of the new investors as listed on the new 8K filing: Don't have time now to research who they are but here's the list: Amount of Shares Number of Warrants Name and Address of Purchasers Purchased Purchased ------------------------------- ----------- -------------------- Platinum Partners Liquid Opportunity Master Fund LP 1,794,944 897,472 152 West. 57th Street 4th Floor New York, NY 10019 Platinum Partners Value Arbitrage Fund LP 1,794,944 897,472 152 West. 57th Street 4th Floor New York, NY 10019 Midsummer Investment, Ltd. 2,222,222 1,111,111 295 Madison Ave., 38th Floor New York, NY 10017 Investor Company 1,666,667 833,334 77 Bloor Street, 3rd Floor Toronto, Ontario Canada M4Y 2T1 Whalehaven Capital Fund Ltd. 555,556 277,778 560 Sylvan Ave., 3rd Floor Englewood Cliffs, NJ 07632 Alpha Capital 1,666,667 833,334 c/o LH Financial Inc. 150 Central Park South 2nd Floor New York, NY 10019 |
|
Kenneth Ho
said:
|
... Your latest article titled "More Details About CEL-SCI's Flu Vaccine & Treatment" cannot be viewed completely. It appears truncated on the right side. Can this please be rectified? Many thanks. |
|
M.E.Garza
said:
|
... I'm not a certified financial analyst so I can't give you concrete price targets. The way swine flu stocks run, anything is possible, especially with news from the company. that being said, it may be another few weeks before we get news from CVM, so keep an eye on volume. If it dries up, then it may dip down. |
|
